Cargando…
Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
OBJECTIVES: Detection of α‐synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α‐synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of α‐synuclein seed amplificati...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187727/ https://www.ncbi.nlm.nih.gov/pubmed/36972727 http://dx.doi.org/10.1002/acn3.51753 |
_version_ | 1785042791056801792 |
---|---|
author | Chahine, Lana M. Beach, Thomas G. Adler, Charles H. Hepker, Monica Kanthasamy, Anumantha Appel, Scott Pritzkow, Sandra Pinho, Michelle Mosovsky, Sherri Serrano, Geidy E. Coffey, Christopher Brumm, Michael C. Oliveira, Luis M. A. Eberling, Jamie Mollenhauer, Brit |
author_facet | Chahine, Lana M. Beach, Thomas G. Adler, Charles H. Hepker, Monica Kanthasamy, Anumantha Appel, Scott Pritzkow, Sandra Pinho, Michelle Mosovsky, Sherri Serrano, Geidy E. Coffey, Christopher Brumm, Michael C. Oliveira, Luis M. A. Eberling, Jamie Mollenhauer, Brit |
author_sort | Chahine, Lana M. |
collection | PubMed |
description | OBJECTIVES: Detection of α‐synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α‐synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of α‐synuclein seed amplification assay in central (cerebrospinal fluid) and peripheral (submandibular gland) sources, compare to total α‐synuclein measures, and investigate within‐subject relationships. METHODS: The Systemic Synuclein Sampling Study aimed to characterize α‐synuclein in multiple tissues and biofluids within Parkinson disease subjects (n = 59) and compared to healthy controls (n = 21). Motor and non‐motor measures and dopamine transporter scans were obtained. Four measures of α‐synuclein were compared: seed amplification assay in cerebrospinal fluid and formalin‐fixed paraffin‐embedded submandibular gland, total α‐synuclein quantified in biofluids using enzyme‐linked immunoassay, and aggregated α‐synuclein in submandibular gland detected by immunohistochemistry. Accuracy of seed amplification assay for Parkinson disease diagnosis was examined and within‐subject α‐synuclein measures were compared. RESULTS: Sensitivity and specificity of α‐synuclein seed amplification assay for Parkinson disease diagnosis was 92.6% and 90.5% in cerebrospinal fluid, and 73.2% and 78.6% in submandibular gland, respectively. 25/38 (65.8%) Parkinson disease participants were positive for both cerebrospinal fluid and submandibular gland seed amplification assay. Comparing accuracy for Parkinson disease diagnosis of different α‐synuclein measures, cerebrospinal fluid seed amplification assay was the highest (Youden Index = 83.1%). 98.3% of all Parkinson disease cases had ≥1 measure of α‐synuclein positive. INTERPRETATION: α‐synuclein seed amplification assay (cerebrospinal fluid>submandibular gland) had higher sensitivity and specificity compared to total α‐synuclein measures, and within‐subject relationships of central and peripheral α‐synuclein measures emerged. |
format | Online Article Text |
id | pubmed-10187727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101877272023-05-17 Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay Chahine, Lana M. Beach, Thomas G. Adler, Charles H. Hepker, Monica Kanthasamy, Anumantha Appel, Scott Pritzkow, Sandra Pinho, Michelle Mosovsky, Sherri Serrano, Geidy E. Coffey, Christopher Brumm, Michael C. Oliveira, Luis M. A. Eberling, Jamie Mollenhauer, Brit Ann Clin Transl Neurol Research Articles OBJECTIVES: Detection of α‐synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α‐synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of α‐synuclein seed amplification assay in central (cerebrospinal fluid) and peripheral (submandibular gland) sources, compare to total α‐synuclein measures, and investigate within‐subject relationships. METHODS: The Systemic Synuclein Sampling Study aimed to characterize α‐synuclein in multiple tissues and biofluids within Parkinson disease subjects (n = 59) and compared to healthy controls (n = 21). Motor and non‐motor measures and dopamine transporter scans were obtained. Four measures of α‐synuclein were compared: seed amplification assay in cerebrospinal fluid and formalin‐fixed paraffin‐embedded submandibular gland, total α‐synuclein quantified in biofluids using enzyme‐linked immunoassay, and aggregated α‐synuclein in submandibular gland detected by immunohistochemistry. Accuracy of seed amplification assay for Parkinson disease diagnosis was examined and within‐subject α‐synuclein measures were compared. RESULTS: Sensitivity and specificity of α‐synuclein seed amplification assay for Parkinson disease diagnosis was 92.6% and 90.5% in cerebrospinal fluid, and 73.2% and 78.6% in submandibular gland, respectively. 25/38 (65.8%) Parkinson disease participants were positive for both cerebrospinal fluid and submandibular gland seed amplification assay. Comparing accuracy for Parkinson disease diagnosis of different α‐synuclein measures, cerebrospinal fluid seed amplification assay was the highest (Youden Index = 83.1%). 98.3% of all Parkinson disease cases had ≥1 measure of α‐synuclein positive. INTERPRETATION: α‐synuclein seed amplification assay (cerebrospinal fluid>submandibular gland) had higher sensitivity and specificity compared to total α‐synuclein measures, and within‐subject relationships of central and peripheral α‐synuclein measures emerged. John Wiley and Sons Inc. 2023-03-27 /pmc/articles/PMC10187727/ /pubmed/36972727 http://dx.doi.org/10.1002/acn3.51753 Text en © 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Chahine, Lana M. Beach, Thomas G. Adler, Charles H. Hepker, Monica Kanthasamy, Anumantha Appel, Scott Pritzkow, Sandra Pinho, Michelle Mosovsky, Sherri Serrano, Geidy E. Coffey, Christopher Brumm, Michael C. Oliveira, Luis M. A. Eberling, Jamie Mollenhauer, Brit Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay |
title | Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay |
title_full | Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay |
title_fullStr | Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay |
title_full_unstemmed | Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay |
title_short | Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay |
title_sort | central and peripheral α‐synuclein in parkinson disease detected by seed amplification assay |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187727/ https://www.ncbi.nlm.nih.gov/pubmed/36972727 http://dx.doi.org/10.1002/acn3.51753 |
work_keys_str_mv | AT chahinelanam centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT beachthomasg centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT adlercharlesh centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT hepkermonica centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT kanthasamyanumantha centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT appelscott centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT pritzkowsandra centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT pinhomichelle centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT mosovskysherri centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT serranogeidye centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT coffeychristopher centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT brummmichaelc centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT oliveiraluisma centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT eberlingjamie centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT mollenhauerbrit centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay AT centralandperipheralasynucleininparkinsondiseasedetectedbyseedamplificationassay |